Bioseka is focused on advanced research and applications of antisense
oligonucleotides (ASOs) as antimicrobial agents against Gram-positive and Gram-negative bacteria. The company’s primary target is control of bacterial biofilms through inhibiting the synthesis of exopolysaccharides, which compose structural matrix of the biofilms.
Bioseka ASOs have potential applications in the therapy of medically
important oral, nasopharyngeal, skin and cardiovascular infections. Bioseka ASOs can also be combined with other antimicrobial agents, thus providing a novel path for combating multidrug-resistant bacteria.
The company is currently developing several lead phosphorothioate
and peptide nucleic acid ASOs and is working to establish the optimum
effective dosage, to improve their penetration into the biofilm and target cells, and to test stability of the chemotherapeutics under various conditions involving the complex environment of natural microbiota.